In vitro inactivation of SARS-CoV-2 using a povidone-iodine oral rinse

BMC Oral Health

Rosa Hong¹  Manjunath Shet²  Sailaja Bhaskar²  David Igo²  Marc Cataldo³  Jonna Westover⁴ 

[1] Avrio Health L.P., New York, NY, USA;Imbrium Therapeutics L.P., Stamford, CT, USA;Purdue Pharma L.P., 06901, Stamford, CT, USA;The Institute for Antiviral Research, Utah State University, Logan, UT, USA;

关键词: Anti-infective agents;    Coronavirus;    Povidone-iodine;    SARS-CoV-2;    Virus inactivation;   

DOI  :  10.1186/s12903-022-02082-9

来源: Springer

【 摘 要 】

BackgroundHealthcare professionals, especially dentists and dental hygienists, are at increased risk for contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through air-borne particles and splatter. This study assessed the in vitro virucidal activity of 0.5% (w/v) povidone-iodine (PVP-I) oral rinse against SARS-CoV-2 to demonstrate its utility as a professional oral rinse.MethodsA 0.5% (w/v) PVP-I oral rinse formulation, placebo oral rinse, and positive (70% [v/v] ethanol and water) and negative (water) controls were assessed using the time-kill method. SARS-CoV-2 was propagated in Vero 76 host cells. Following neutralization validation, triplicate tests were performed for each test formulation and virucidal activity measured at 15, 30, and 60 s and 5 min.ResultsThe 0.5% (w/v) PVP-I oral rinse demonstrated effective in vitro virucidal activity against SARS-CoV-2 as early as 15 s after exposure; viral titer was reduced to < 0.67 log10 50% cell culture infectious dose (CCID50)/0.1 mL (log10 reduction of > 4.0) at 30 s, whereas the placebo oral rinse reduced the SARS-CoV-2 viral titer to 4.67 and 4.5 log10 CCID50/0.1 mL at the 15- and 30-s time points, with a log10 reduction of 0.63 and 0.17, respectively. No toxicity or cytotoxic effects against Vero 76 host cells were observed with the 0.5% (w/v) PVP-I oral rinse; positive and negative controls performed as expected.ConclusionsIn vitro virucidal activity of 0.5% (w/v) PVP-I oral rinse against SARS-CoV-2 was demonstrated. Rapid inactivation of SARS-CoV-2 was observed with 0.5% (w/v) formulation with a contact duration of 15 s. Clinical investigations are needed to assess the effectiveness of PVP-I oral rinse against SARS-CoV-2 in dental practice.

【 授权许可】

CC BY